Literature DB >> 8223480

Functional analysis of pre-mRNA splicing factor SF2/ASF structural domains.

J F Cáceres1, A R Krainer.   

Abstract

Human pre-mRNA splicing factor SF2/ASF has an activity required for general splicing in vitro and promotes utilization of proximal alternative 5' splice sites in a concentration-dependent manner by opposing hnRNP A1. We introduced selected mutations in the N-terminal RNA recognition motif (RRM) and the C-terminal Arg/Ser (RS) domain of SF2/ASF, and assayed the resulting recombinant proteins for constitutive and alternative splicing in vitro and for binding to pre-mRNA and mRNA. Mutants inactive in constitutive splicing can affect alternative splice site selection, demonstrating that these activities involve distinct molecular interactions. Specific protein-RNA contact mediated by Phe56 and Phe58 in the RNP-1 submotif of the SF2/ASF RRM are essential for constitutive splicing, although they are not required for RRM-mediated binding to pre-mRNA. The RS domain is also required for constitutive splicing activity and both Arg and Ser residues are important. Analysis of domain deletion mutants demonstrated strong synergy between the RRM and a central degenerate RRM repeat in binding to RNA. These two domains are sufficient for alternative splicing activity in the absence of an RS domain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223480      PMCID: PMC413916          DOI: 10.1002/j.1460-2075.1993.tb06160.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  63 in total

1.  Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit.

Authors:  M Zhang; P D Zamore; M Carmo-Fonseca; A I Lamond; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

Review 2.  The RNP motif protein family.

Authors:  S R Haynes
Journal:  New Biol       Date:  1992-05

3.  General splicing factors SF2 and SC35 have equivalent activities in vitro, and both affect alternative 5' and 3' splice site selection.

Authors:  X D Fu; A Mayeda; T Maniatis; A R Krainer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

4.  ASF alternative transcripts are highly conserved between mouse and man.

Authors:  R Tacke; A Boned; C Goridis
Journal:  Nucleic Acids Res       Date:  1992-10-25       Impact factor: 16.971

Review 5.  Autoregulation and multifunctionality among trans-acting factors that regulate alternative pre-mRNA processing.

Authors:  W Mattox; L Ryner; B S Baker
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

Review 6.  RNA processing.

Authors:  D C Rio
Journal:  Curr Opin Cell Biol       Date:  1992-06       Impact factor: 8.382

7.  Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site.

Authors:  J Carey; V Cameron; P L de Haseth; O C Uhlenbeck
Journal:  Biochemistry       Date:  1983-05-24       Impact factor: 3.162

8.  Cloning and characterization of PSF, a novel pre-mRNA splicing factor.

Authors:  J G Patton; E B Porro; J Galceran; P Tempst; B Nadal-Ginard
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

9.  Diminished peripheral blood monocyte DR antigen expression in systemic lupus erythematosus.

Authors:  H Nagai; M B Sztein; P S Steeg; J J Hooks; J J Oppenheim; A D Steinberg
Journal:  Clin Exp Rheumatol       Date:  1984 Apr-Jun       Impact factor: 4.473

10.  Multiple factors including the small nuclear ribonucleoproteins U1 and U2 are necessary for pre-mRNA splicing in vitro.

Authors:  A R Krainer; T Maniatis
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

View more
  117 in total

1.  The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers.

Authors:  Y Cavaloc; C F Bourgeois; L Kister; J Stévenin
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

2.  Genetic analysis of functional domains within the Drosophila LARK RNA-binding protein.

Authors:  G P McNeil; A J Schroeder; M A Roberts; F R Jackson
Journal:  Genetics       Date:  2001-09       Impact factor: 4.562

Review 3.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

4.  The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.

Authors:  Vita Dauksaite; Göran Akusjärvi
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

5.  Multiple properties of the splicing repressor SRp38 distinguish it from typical SR proteins.

Authors:  Chanseok Shin; Frida E Kleiman; James L Manley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  The Drosophila U1-70K protein is required for viability, but its arginine-rich domain is dispensable.

Authors:  Helen K Salz; Ricardo S Y Mancebo; Alexis A Nagengast; Olga Speck; Mitchell Psotka; Stephen M Mount
Journal:  Genetics       Date:  2004-12       Impact factor: 4.562

7.  Negative feedback regulation among SR splicing factors encoded by Rbp1 and Rbp1-like in Drosophila.

Authors:  Supriya Kumar; A Javier Lopez
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

8.  A proposed signaling motif for nuclear import in mRNA processing via the formation of arginine claw.

Authors:  Donald Hamelberg; Tongye Shen; J Andrew McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-06       Impact factor: 11.205

9.  Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation.

Authors:  D T Stolow; S R Haynes
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

10.  A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers.

Authors:  B R Graveley; K J Hertel; T Maniatis
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.